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Abstract
Background: Coronary heart disease and depression are both common health problems and by 2020 will be the
two leading causes of disability worldwide. Depression has been found to be more common in patients with
coronary heart disease but the nature of this relationship is uncertain. In the United Kingdom general practitioners
are now being remunerated for case-finding for depression in patients with coronary heart disease, however it is
unclear how general practitioners should manage these patients. We aim to explore the relationship between
coronary heart disease and depression in a primary care population and to develop an intervention for patients
with coronary heart disease and depression.
Methods/design: This programme of research will consist of 4 inter-related studies. A 4 year prospective cohort
study of primary care patients with coronary heart disease will be conducted to explore the relationship between
coronary heart disease and depression. Within this, a nested case-control biological study will investigate genetic
and blood-biomarkers as predictors of depression in this sample. Two qualitative studies, one of patients’
perspectives of treatments for coronary heart disease and co-morbid depression and one of primary care
professionals’ views on the management of patients with coronary heart disease and depression will inform the
development of an intervention for this patient group. A feasibility study for a randomised controlled trial will then
be conducted.
Discussion: This study will provide information on the relationship between coronary heart disease and depression
that will allow health services to determine the efficiency of case-finding for depression in this patient group. The
results of the cohort study will also provide information on risk factors for depression. The study will provide
evidence on the efficacy and feasibility of a joint patient and professional led intervention and data necessary to
plan a definitive randomised controlled trial of the intervention.
Background
The World Bank and World Health Organisation have
predicted that by 2020, coronary heart disease (CHD)
and depression will be the two top causes of global
health burden and disability[1]. As well as causing per-
sonal suffering, depression is a major public health
problem responsible for 100 million lost working
days in England and Wales at a cost of £9 billion per
annum [2].
In the United Kingdom (UK), depression is one of the
commonest reasons for consulting a general practitioner
(GP). Up to 17% of consecutive GP attendees suffer
from depression [3]. In the UK, 95% of people suffering
from depression are treated solely in primary care [4].
Depression has been found to be more common in
patients with coronary heart disease (CHD) with a pre-
valence of 20% [5]. Depression also increases the inci-
dence and recurrence of acute coronary syndromes and
death in patients with heart disease [5]. This increase in
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cardiac risk is independent of other risk factors for CHD
[5]. The reason for the increased morbidity and mortal-
ity is unclear but may be due to increased activity of the
immune/inflammatory pathways in depression, activat-
ing atherogenesis and plaque formation [6].
Depression is associated with a 50% increase in the
costs of long term medical care after controlling for the
severity of the physical illness[7]. Some of these costs
are related to the association between depression and
adverse health risk behaviours such as smoking, diet,
lack of exercise and a lack of adherence to self-care
regimes. Depression as cause or consequence of physical
illnesses such as CHD may exacerbate the perceived
severity of symptoms and with an increase in health ser-
vice utilisation[7]. Treating depression and improving
outcomes for depression has been shown to reduce
health costs in people with physical illness[7,8]. It there-
fore seems important to address the care of patients
with coronary heart disease and co-morbid depression
in the primary care setting.
In the UK, GPs are now remunerated for depression
case-finding in patients with CHD [9]. This is because
evidence from two large trials in the United States has
provided an indication in post hoc sub-group analyses
that there may be cardiovascular benefits from treating
depression using antidepressant medication[10,11]. Mor-
tality seems to have been reduced in those whose
depression improved and in those who took sertraline
[12,13]. However, the natural history, morbidity and
mortality of depression in the primary care population
of patients with CHD are not known. It is also unclear
how primary care professionals should manage addi-
tional cases of depression that may be identified in their
CHD patients. Observational cohort studies are needed
to help determine the effect of policy implementation
on the patient’s cardiac and depression outcomes as
well as the effects of co-morbidity on morbidity and
mortality. If the incidence of depression in patients with
CHD is not solely a function of the current physical sta-
tus, a cohort study will enable other factors associated
with the incidence of depression e.g. factors relating to
quality of life, illness attribution and social support, to
be determined.
There are a number of treatment options for mana-
ging depression in primary care e.g. antidepressant med-
ication, supervised exercise, guided self help, problem
solving, computerised cognitive behavioural therapy
(cCBT), group or individual CBT or interpersonal ther-
apy (IPT) [4]. However the treatment preferences of
patients with CHD are unknown. Primary care profes-
sional treatment preferences for managing depression in
this population are also unknown. As with most physical
illness in primary care settings, it is also unclear where
the boundary exists between distress secondary to the
physical condition and depression that would benefit
from treatment. Qualitative studies with patients and
their primary care professionals are needed to explore
this further. A recent working party on the management
of depression in CHD concluded that randomised con-
trolled trials of stepped depression care versus treatment
as usual for patients with CHD and depression are
needed [5]. This programme of research will inform a
randomised controlled trial of the effectiveness and
cost-effectiveness of a case management approach to
manage primary care patients with coronary heart dis-
ease and co-morbid depression. Case management has
been shown to improve outcomes for depression in pri-
mary health-care settings [14], but there has been no
research to determine whether it is effective in patients
with symptomatic coronary heart disease. Case manage-
ment has been defined as ‘taking responsibility for fol-
lowing-up patients; determining whether patients were
continuing the prescribed treatment as intended; asses-
sing whether depressive symptoms were improving; tak-
ing action when patients were not adhering to guideline
based treatment or were not showing expected improve-
ment’[15]. It consists of five essential components [14]:
1. identification of patients in need of services
2. Assessing individual patient’s needs
3. Developing a treatment plan
4. Coordination of care
5. Monitoring outcomes and altering care when
favourable outcomes are not achieved
A randomised controlled trial is necessary to deter-
mine whether case management for this population is
more effective than treatment as usual both in terms of
depression and cardiac outcomes. A pilot randomised
controlled trial is needed first to inform the design of
the definitive randomised control trial.
This protocol describes a programme of research to
develop and test a stepped care intervention for depres-
sion and coronary heart disease in primary care. It con-
sists of 4 inter-related studies.
1. A 4 year cohort study of patients with coronary
heart disease
2. A qualitative study of patients with coronary heart
disease and co-morbid depression treatment preferences
3. A qualitative study of general practitioners (GPs)
and practice nurses (PNs) treatment preferences for this
patient group
4. A pilot randomised controlled trial of a case man-
agement programme for depressed primary care patients
with CHD.
The first three studies will inform the development of
the pilot randomised controlled trial (study 4). As the
four studies are closely related and the randomised
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controlled trial depends on the conduct and findings of
the other studies, the study protocols will be described
in turn.
Study 1: Cohort Study
Objectives
The objectives of the cohort study are to:
• Determine prevalence, incidence rate and risk fac-
tors of depression in primary care patients with
CHD
• Explore and describe the course, relationship,
prognosis and current management of physical and
depressive symptoms in primary care patients with
CHD and co-morbid depression over a four-year
period.
• To determine the effect of co-morbid depression
on mortality, symptom severity, quality of life, dis-
ability, pain, service use (at all levels) and service
costs, and lost employment costs in primary care
patients with CHD.
•In a subsample, to investigate genetic variation and
blood biomarkers that characterise depression in this
cohort.
Hypotheses
In addition to the estimation of prevalence and inci-
dence of depression among patients with CHD, the
main hypotheses to be tested in this study are:
• That symptoms and disability caused by CHD are
associated with depression and that in patients with
symptomatic CHD, the severity of symptoms of
CHD, is a greater predictor of developing a depres-
sive episode than a past history of depression.
• That in patients with symptomatic CHD, the sever-
ity of depressive symptoms as measured by the Hos-
pital Anxiety and Depression Scale (HADS) [16] is
related to the severity of CHD symptoms as mea-
sured by the Rose Angina Questionnaire [17] and
SF-36[18].
• That patients with CHD and depression use more
services for the management of their CHD, are more
costly, and have higher lost employment costs than
non-depressed primary care patients with CHD.
Methods/design
This is a naturalistic cohort study in primary care in
South London, United Kingdom. Eligible consenting
patients will be assessed at baseline and then at 6
monthly intervals for up to 4-years.
Study Population
Patients with CHD will be recruited from practice CHD
registers. Two subgroups will be identified:
1. Patients with CHD and a current diagnosis of
depression
2. Patients with CHD who are not currently depressed
Recruitment of study population
GPs are remunerated for keeping CHD registers under
the Quality and Outcomes Framework. Practices parti-
cipating in this Framework and based in South London
will be recruited by the Greater London Research Net-
work (GLRN). All patients on the CHD registers in
participating general practices will be invited to partici-
pate in the study. Consenting patients will be assessed
at baseline and then every 6 months over a 4 year
period.
Measures
Information on sociodemographic status, past medical
and psychiatric history, prescribed medication and
medication compliance will be collected. Measures
used at baseline and follow-ups [17-31] are shown in
Table 1.
In addition, for the nested biological study we will
investigate “at risk” genetic polymorphisms in neuro-
transmitters and immune genes (for example, serotonin
transport or interleukin-6) and inflammatory biomarkers
(for example, C-reactive protein and cortisol).
Inclusion criteria
• Currently registered with GP
• On the coronary heart disease register of participat-
ing general practitioners
• Over 18 years of age
Table 1 Measures that will be used at baseline and
follow-up assessments
Measure Baseline Follow-
up
Modified Rose Angina Questionnaire [17] x x
Guy’s Hospital Chest Pain Questionnaire [19] x x
Specific Activity Scale[20] x x
General Health Questionnaire-12 (GHQ-12_ [21] x
Hospital Anxiety and Depression Scale (HADS)[22] x x
Clinical Interview Schedule-Revised (CIS-R) [23] x
Patient Health Questionnaire-9 (PGQ-9) [24] x x
EuroQoL (EQ-5D) [25] x x
Medical Outcomes Survey Short Form-12 (SF-12) [18] x x
List of Threatening Experiences Questionnaire [26] x x
Social Problems Questionnaire (SPQ) [27] x x
Client Service Receipt Inventory (CSRI) [28] x x
Brief Illness Perceptions Questionnaire (B-IPQ) [29] x x
Psychological Outcome Profiles Questionnaire
(PSYCHLOPS) [30]
x x
Rapid Estimate of Adult Literacy in Medicine
(REALM) [31]
x
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Exclusion criterion
• Patients only temporarily registered with participating
practices
Sample size calculation
The national prevalence of CHD in primary care as esti-
mated by the Quality and Outcomes Framework (QOF)
disease registers is 3.5%. We estimate that in patients
with CHD, 20% will have a diagnosis of depression.
In a practice population of 10,000 people, we would
therefore expect 350 patients with CHD of which 70
would be currently be depressed. Three practices with
an average population of 10,000 patients will be
recruited initially. Allowing for 80% participation, this
will provide ~ 670 patients with CHD but no depression
and ~168 patients with CHD and co-morbid depression.
A cohort of this size would be large enough to estimate
rates to acceptable limits on the basis of the above fig-
ures. The total sample size (~800) would produce up to
4800 data points over 4 years of follow-up at 6-monthly
intervals (6 measures per person). This total sample size
will be effectively somewhat smaller, firstly because of
attrition and secondly because of the lack of indepen-
dence of the repeated measures. Assuming an intra-per-
son correlation of 0.2, the sample size would reduce by
approximately 1/3 and if 20% dropout is also assumed, a
total sample size of ~3130 data points would be col-
lected, large enough to allow modelling of the associa-
tions between physical and mental illness as specified in
the hypotheses.
Analysis
A descriptive analysis of prevalence and incidence,
course, prognosis and management of physical and
depressive symptoms will be undertaken. Risk and rate
ratios will be estimated for the effect of depression on:
symptom severity, quality of life, functional status, pain,
and service use. An economic evaluation will be con-
ducted to establish economic burden. Multiple regres-
sion using methods for repeated measures will be used
to explore the relationship between depression, CHD
and other possible confounding factors using the longi-
tudinal data. The time course will be examined by
including time as a main effect and as an interaction
with the physical illness. The relationship of depression
severity to outcome measures will also be explored
using multiple regression analyses.
Service costs will be calculated by combining service
use data from the Client Service Receipt Inventory with
appropriate unit cost information. Lost employment
costs will be estimated by multiplying lost workdays by
daily wage rates. Regression models will be used to iden-
tify patient characteristics that explain variations in
costs. Due to the expected skewed distribution of the
cost data we will use bootstrapping and generalised lin-
ear models. It would be expected that service inputs
over time (represented by service costs) would influence
clinical measures and quality of life. To assess this we
will also use regression models with symptoms and
quality of life as dependent variables and the costs of
specific services entered as independent variables, along
with socio-demographic covariates.
Time Scale
The cohort study will run for up to 4 years. The Pro-
gramme is a five-year study, the first 6 months will be
spent obtaining the necessary ethics and research gov-
ernance approvals and the final year will be spent ana-
lysing the data, writing up and dissemination. The
cohort study will therefore, in effect, run for three and a
half years allowing at least 6 follow-up data points after
the initial baseline assessments supposing that patients
are enrolled into the cohort by 12 months from the
start of the study.
Ethical approval
This study was granted ethical approval by the Bexley
and Greenwich Research Ethics Committee (REC Refer-
ence: 07/H0809/38)
Study 2: A Qualitative Study of patients’
perceptions of distress and depression in patients
with CHD
Aims
The second study in the Up-Beat Programme is a quali-
tative study of the perceptions of depression and distress
in patients with CHD who have significant depressive
symptoms. The aim of this study is to elicit patients’
perceptions of their psychological state as linked to their
CHD and explore their views on appropriate treatments
for distress or depression in the context of their CHD.
A second aim is to explore particular distinctions they
may make between distress and depression.
Sample
Up to fifty people will be purposively sampled from the
cohort study based on age, gender, practice, CHD status,
and depression severity.
Method/design
Consenting participants will have a semi-structured
interview partly informed by an initial focus group of
patients with symptoms of depression and co-morbid
CHD. The interview will also cover:
• A description of the participant’s current psycholo-
gical state
• What treatments they think are appropriate for
depression/psychological distress?
• How participants may prevent or take protective
measures in the context of both CHD and distress/
depression
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• The views of participants on medication for both
their heart condition and depression
Analysis
The interviews will be audio-taped and transcribed ver-
batim. The analysis will be assisted by computer software,
namely, NVivo7 (QSR International, 2006). A thematic
analysis of the data will be conducted. The themes will
be guided by the data but there will be two a priori areas
of investigation; firstly the links made by the participant
between their physical condition and their psychological
state; secondly which treatments, if any, they think are
appropriate? Discourse Analysis will be used to explore
how participants think about their psychological state
and to examine the language they use. Their use of lan-
guage will be used to help develop a scale to differentiate
between distress and depression as below.
Developing a scale to differentiate distress and
depression
A pilot scale, based on the analysis above, will be con-
structed that can be used to differentiate between distress
and depression in primary care clinical practice. Focus
groups will be convened to assess the validity of the scale.
The scale will be factor analysed to see if there is a two-
factor solution - one for distress and one for depression.
The correlation of the scale, and sub-scales with a quanti-
tative measures of depression will be assessed. A merged
factor analysis on both the quantitative and patient-gener-
ated scales together will then be undertaken.
Ethical approval
This study was granted ethical approval by the Bexley
and Greenwich Research Ethics Committee (REC Refer-
ence: 07/H0809/38)
Study 3: A Qualitative Study of health
professionals’ perceptions of distress and
depression in patients with CHD
Objectives
The objectives of the third study in the Up-Beat pro-
gramme are:
1. To explore primary care professionals’ views on dis-
tress and depression in patients with CHD
2. To explore their current management strategies and
attitudes to a range of treatments in relation to this
patient group
3. To provide guidance on the design and implemen-
tation of a practice-nurse led case-management depres-
sion intervention.
Method/design
Individual in-depth interviews will be conducted with up
to 20 general practitioners and practice nurses in
primary care centres in South London. The sample will
be selected purposively to include professionals working
in different settings (single-handed and group practices)
serving areas of contrasting socio-economic, gender and
ethnic characteristics. Potential participants will be
invited to take part in an interview with the aim of
exploring primary care professionals’ perceptions of dis-
tress and depression in patients with coronary heart dis-
ease. An initial interview guide will be developed from
the research literature. Key topics to be explored in the
interviews are likely to include:
• Observations on the impact of distress and depres-
sion on help-seeking in patients with CHD
• Perceptions of the presentation of distress/depres-
sion in people with CHD, including patients’ beliefs
and attributions
• Age, gender, ethnic and cultural differences in the
above
• Vulnerability and risk factors for depression in
patients with CHD, including social and economic
factors
• Current management strategies, including primary
and secondary care interventions, patient self-care
and non-medical or “life-style” strategies
• Attitudes to various treatment options, including
practice-nurse led case-management
Interviews will be recorded on audiotape and tran-
scribed verbatim. The interviewing and analysis pro-
cedure will be based on grounded theory principles in
which theories are generated from themes identified
in the analysis of participant interviews [32]. At least
two researchers will read the transcripts of early
interviews several times to immerse themselves in the
data and then independently identify and give a
descriptive “code” to relevant sections of the text.
They will then compare their coding and any discre-
pancies will be discussed and resolved. An iterative
procedure is followed in which new themes emerging
from interviews are added to the coding frame and
earlier transcripts recoded. New themes will be added
to the interview guide to be explored in later inter-
views. The computer programme NVivo 7 (QSR
International, 2006) will be used to process the tran-
scripts, code themes systematically and explore the
associations between them.
Using key findings to inform the development of an
intervention
Key findings from the interview study will be used in
informing the choice and content of the pilot interven-
tion for the randomised controlled trial using the fol-
lowing approach:
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Choice of intervention
• Findings and recommendations from qualitative stu-
dies 2 and 3 will be assessed by an intervention work-
ing group, consisting of members of the research team
and steering group. These will then inform the content
and delivery of the case management intervention.
Patient participation via two focus groups
• A purposive sample of 8-10 qualitative interview par-
ticipants will be selected to take part in 2 consecutive,
focus groups, using the same sample for each group.
• The aim of the first group is to discuss the pro-
posed pilot intervention and elicit suggestions for
additions and/or alterations to the proposed content.
• The aim of the second group is to re-present the
amended pilot intervention content and to elicit final
comments and minor alterations that may be needed.
Ethical approval
This study was granted ethical approval by the Bexley
and Greenwich Research Ethics Committee (REC Refer-
ence: 07/H0809/38)
Study 4: Feasibility study for a randomised
controlled trial of case management for
depression in primary care patients with
symptomatic coronary heart disease
Objectives
The objectives of this pilot are:
1. Clinical efficacy of case management
To explore whether case management for primary care
patients with symptomatic coronary heart disease and
depression, when delivered by mental health profes-
sionals may be more effective than treatment as usual.
2. Sample size calculation
Estimates of the location of the mean and variability
around the mean (standard deviation) for the pri-
mary outcome measure (see measures) will be calcu-
lated. A conservative estimate using the 95% upper
confidence limit will be used to inform the sample
size calculation of the definitive RCT.
3. To enable selection of the most appropriate pri-
mary and secondary outcome measures. The pilot
will also allow potential secondary outcome mea-
sures to be assessed.
4. Integrity of the study protocol
The pilot will allow all procedures for a definitive effec-
tiveness RCT to be piloted. This will include testing:
• inclusion/exclusion criteria
• training of staff in the administration and
assessment of the intervention.
5. Testing data collection forms and questionnaires
This will ensure that the questionnaires are accepta-
ble to the participants, are comprehensible, appro-
priate, clearly defined and presented in a consistent
manner. Patient information documents and consent
forms will also be tested. Inter-rater reliability
between researchers will be tested.
6. Randomization procedure
The randomisation process and acceptability of ran-
domisation to primary care professionals and partici-
pants will be tested.
7. Recruitment and consent
The recruitment method will be tested and the con-
sent rate for participants into the study calculated. Bar-
riers to recruitment of both practices and participants
will be explored. Follow-up rates will be calculated.
8. To determine the acceptability of the intervention
and the trial to practices and participants. To deter-
mine the possible sources of contamination, and to
develop a standardised manual for case management
for use in the definitive RCT. To make an informal
assessment of the degree to which the intervention
can be standardised and whether therapist effects are
likely to be a major factor.
Method/design
This will be a pilot randomised controlled trial con-
ducted in primary care. A descriptive account of the
process and participants will be recorded.
Setting and Practice recruitment
The study will be carried out in primary care. Practices
in South London which are not participating in the
cohort study will be recruited via the Greater London
Primary Care Research Network (PCRN-GL) and invited
to participate in the pilot study. We estimate from the
results of the cohort study that we will need 10-15 prac-
tices each with around 10,000 patients in order to ran-
domise between 30 and 50 participants per arm.
Participant recruitment
All patients on practice case registers for CHD will be
asked by their GP for consent to contact from a
researcher. Those consenting will be contacted by a
researcher and assessed for depression using the Patient
Health Questionnaire-2[33] and for symptoms relating
to CHD using the Modified Rose Angina Questionnaire
[34]. Patients scoring 3 or more on the PHQ-2, and
with symptomatic CHD will then be assessed further
using the Hospital Anxiety and Depression Scale
(HADS)[22]. If they score >9 on the depression scale of
HADS they will be eligible to participate in the study.
Those consenting to participate will then be randomised
to either to the intervention (case management) or the
treatment as usual (TAU) arm of the study.
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Sample size
If we want to show a mean difference between interven-
tion and control of ≥ 3 on the HADS Depression sub-
scale, assuming a standard deviation around mean
scores of 4, we will need 30 participants per group for
90% power at the 95% significance level. Therefore 60
participants (30 per arm) will be recruited into the RCT.
Inclusion Criteria (Practices)
• Practice keeps a register of patients with CHD for
the Quality and Outcomes Framework (QOF) and is
willing to liaise over patients in the case manage-
ment arm when necessary
Inclusion Criteria (Participants)
• Symptomatic CHD as scored on the modified Rose
Angina Questionnaire
• A score ≥8 on the depression part of the Hospital
Anxiety and Depression Scale
• Aged 16 years or over
Exclusion Criteria (Participants)
• Temporary registrations
• Actively suicidal patients
• Psychotic depression as evidenced by delusions
and/or hallucinations
• Non-English speaking
• Participants currently in hospital for treatment of
their CHD
Up to 20 group practices of around 10,000 patients
each from South London will be recruited by the
Greater London Local Research Network (GLLRN) to
participate in the study.
Intervention
The nature of the intervention will be determined by the
results of the two qualitative studies.
Control
Participants randomised to the TAU control group will
receive treatment as usual by their GP and any other
relevant professionals.
Measures
Participants will be followed up at 1-, 6- and 12-months
post randomisation. The same measures will be applied
at each follow-up. The measures to be used are shown
in Table 2.
In order to evaluate the process of delivering the inter-
vention, focus groups of participants in the intervention
arm and primary care professionals will be conducted to
explore their experiences, views on the intervention, and
their experience of participating in this study.
Randomisation
The unit of randomisation will be the participant. Ran-
domisation will be conducted independently by the
Clinical Trials Unit at the Institute of Psychiatry, King’s
College London. Randomisation will be by random per-
muted blocks.
Blinding
Researchers will be blind to randomisation status.
Researchers will be asked to give their opinion on ran-
domisation status at the end of the study to determine
whether blinding was adequate.
Statistical analysis
Descriptive analyses will be used to provide summary
estimates of outcome measures, focussing on the drop-
out rate at each time point, the order of magnitude of
the effect of the intervention and the variability of the
outcome measure at baseline. T-tests and regression
modelling will be used to test whether there is a statisti-
cally significant difference between intervention and
control groups. All analyses will be by intention to treat.
While the sample size will not be sufficient to test clus-
tering effects formally, sources of clustering will be iden-
tified so that they can be taken into account in a
definitive RCT.
Ethical considerations
Ethical approval has been granted by the South East
London Research Ethics Committee (REC Ref No. 10/
H0808/51).
Participants may withdraw from the study at any time
and without giving any reason without their care being
affected. Any participant thought to be suicidal, either
by the researchers (as assessed on depression question-
naires), or by the case managers will have their GP
Table 2 Measures to be used at each time point in the
pilot randomised controlled trial
Outcome
Parameter
Instruments
Primary Outcome
Depression Hospital Anxiety and Depression Scale[22]
Secondary Outcome
Depression Patient Health Questionnaire-9 [24]
Coronary Heart
Disease
Rose Angina Questionnaire[17], Guy’s Hospital
Chest pain Questionnaire[19], Specific Activity
Schedule [20]
Quality of Life Euroqol-5D [25], Medical Outcomes Survey Short
Form-12 (SF-12) [18]
Adherence to
medication
Adapted version of Morisky adherence
questionnaire[35]
Life events List of Threatening Events Questionnaire [26]
Social problems Social Problems Questionnaire [27]
Health Service
Utilisation
Client Service Receipt Inventory (CSRI) [28]
Illness Perceptions Brief Illness Perceptions Questionnaire [29]
Wellbeing Warwick-Edinburgh Mental Well-being Scale [36]
Participants problem
priorities
PSYCHLOPS [37]
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informed immediately. Case managers will have regular
supervision by clinicians experienced in general practice
and psychiatry employed on the research team. The
team also has an experienced consultant cardiologist to
provide advice where appropriate.
Discussion
We have described the rationale and protocol for a pro-
gramme of research into coronary heart disease and
depression in primary care. This programme has been
funded and is currently underway. This programme of
research should provide important data to help improve
the management of primary care patients with co-mor-
bid CHD and depression. As far as we are aware this
will be the first research into coronary heart disease and
depression in the primary care population. This is
important as in the United Kingdom the majority of
patients with depression are treated entirely in primary
care. A strong point in the design of this research is
that the cohort study will be large enough and con-
ducted over a long enough period of time to be able to
explore potential associations between depression and
coronary heart disease and to determine morbidity and
mortality in this patient group. The nature of the inter-
vention will take into account patient perspectives as
well as health professional perspectives. This should
allow the development of an intervention that also
addresses the concerns of patients. A potential limita-
tion of the research is that it is difficult to estimate
recruitment rates into the cohort study as these vary
widely in the literature. A low recruitment rate could
mean that our cohort is not representative of the gen-
eral practice population with coronary heart disease and
depression. We will however test how representative our
cohort is by comparing it with routinely collected gen-
eral practice data from within the same catchment area
as the study cohort.
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